Celgene Corp. said its anti-inflammatory drug Ozanimod, or RPC1063, showed benefit in patients with Crohn's disease and ulcerative colitis.
In the phase 2 STEPSTONE study, 43% of the patients using Ozanimod saw a 25% decrease in Crohn's disease, while 27% of patients saw a reduction of 50% after 12 weeks.
In the phase 2 TOUCHSTONE study, 91% of ulcerative colitis patients at week 92 had little or no active disease. The most common adverse effects were ulcerative colitis flare, anemia, upper respiratory tract infection and back pain.
The results will be presented at the 2017 World Congress of Gastroenterology in Orlando, Fla.